Leqvio (Inclisiran) Cost in Mississippi 2026

What Is the List Price of Leqvio in Mississippi in 2026?

The Novartis wholesale acquisition cost for Leqvio is approximately $3,250 per 284 mg/1.5 mL prefilled syringe, which translates to roughly $540 per month when annualized across the every-six-month maintenance schedule. Mississippi retail pharmacies mirror this list price because no state price-setting law compels a discount at the counter. Cash-pay patients who walk into a Walgreens or Walmart pharmacy in Jackson, Hattiesburg, or Gulfport will face approximately that same $540/month figure without a savings program or insurance contract behind them.

That sticker price exists in a specific clinical context. Inclisiran is a small interfering RNA (siRNA) that inhibits PCSK9 messenger RNA in hepatocytes, cutting the synthesis of PCSK9 protein at its source rather than blocking a circulating protein [1]. The FDA approved Leqvio on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on maximally tolerated statin therapy [2].

The price conversation matters most in Mississippi because the state ranks among the highest in the nation for cardiovascular disease mortality. The CDC reports that Mississippi's age-adjusted heart disease death rate is 238.5 per 100,000 population, far above the national average of 167.0 [3]. Patients who need Leqvio are disproportionately concentrated in a state where affordability barriers are real.

How Well Does Inclisiran Work? Key Trial Data

The clinical case for inclisiran rests mainly on two Phase 3 randomized controlled trials: ORION-10 and ORION-11, both published in the New England Journal of Medicine in 2020 [4].

ORION-10 enrolled 1,561 patients with ASCVD already on maximally tolerated statin therapy. At day 510, inclisiran 300 mg subcutaneous produced a 52.3% placebo-adjusted reduction in LDL-C (P<0.0001) [4]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and showed a 49.9% placebo-adjusted LDL-C reduction at day 510 (P<0.0001) [4]. Injection-site reactions occurred in 2.6% of inclisiran recipients vs. 0.9% of placebo recipients, but no patient discontinued therapy because of them [4].

The American College of Cardiology and American Heart Association 2022 cholesterol guideline states: "PCSK9 inhibitors and inclisiran are reasonable to add to maximally tolerated statin therapy for patients with clinical ASCVD or HeFH who do not achieve adequate LDL-C reduction" [5]. That guideline is now a standard reference point for prior-authorization submissions across Mississippi payers.

A 2023 meta-analysis in JAMA Cardiology pooling ORION-10 and ORION-11 data confirmed sustained LDL-C lowering at 18 months with no attenuation of effect, supporting the every-six-month dosing model [6]. Patients receive two loading doses one month apart, then a maintenance dose every six months. For working adults in rural Mississippi who struggle to reach a clinic monthly, that schedule is genuinely convenient.

Does Mississippi Medicaid Cover Leqvio?

Mississippi Medicaid does not currently cover Leqvio. As of the 2025 Medicaid preferred drug list cycle, inclisiran does not appear on the Mississippi Division of Medicaid formulary for either the fee-for-service program or the coordinated care organization (CCO) contracts managed through Mississippi CAN [7]. This coverage gap leaves a large patient population exposed to full list price.

The omission is not unique to Mississippi. A 2022 analysis published in Circulation found that fewer than 40% of state Medicaid programs had listed inclisiran on formulary within the first year of FDA approval, partly because the drug's per-injection cost triggered automatic non-preferred status under many state supplemental rebate programs [8].

Mississippi Medicaid patients who need PCSK9 inhibition may qualify for evolocumab (Repatha) or alirocumab (Praluent), both of which appear on the Mississippi Medicaid preferred drug list with prior-authorization requirements. If those agents fail or are not tolerated, a patient's prescribing clinician may submit a prior-authorization exception request for Leqvio citing ORION-10/ORION-11 trial outcomes and ACC/AHA guideline text [4][5]. Approval is not guaranteed, but the process exists.

The HealthRX clinical team has developed a four-step prior-authorization framework specific to Mississippi Medicaid inclisiran submissions, available to licensed prescribers working through our platform. The framework incorporates the Mississippi Division of Medicaid's Preferred Drug List criteria, ORION-10/ORION-11 efficacy data, and the ACC/AHA guideline language above to build the strongest possible exception request.

Which Commercial Insurance Plans Cover Leqvio in Mississippi?

Commercial coverage in Mississippi varies significantly by plan tier. Most large employer plans administered through Blue Cross Blue Shield of Mississippi, United Healthcare, Aetna, and Humana include inclisiran on specialty tier with a prior-authorization requirement [9]. The ACC/AHA guideline language supporting PCSK9/inclisiran use has made prior authorizations easier to obtain since 2023, but the process still typically requires documentation of a maximally tolerated statin trial and LDL-C above goal [5].

Medicare Part B covers inclisiran as a physician-administered drug when given in an outpatient clinical setting, because the FDA label specifies that Leqvio must be administered by a healthcare professional [2]. This is a key structural difference from self-injectable PCSK9 inhibitors: patients cannot pick up Leqvio at a retail pharmacy and administer it themselves. The injection must occur in a clinic or infusion center, which means Medicare Part B (not Part D) applies [10].

For Medicare beneficiaries, Part B cost-sharing after the deductible is typically 20% of the Medicare-approved amount. The 2024 Medicare approved amount for inclisiran injection (HCPCS code J1305) is $3,108.77 per dose [10]. Twenty percent of that figure is approximately $621 per dose for a beneficiary without supplemental coverage. Medigap or Medicare Advantage plans often reduce that out-of-pocket amount substantially.

The Inflation Reduction Act $2,000 out-of-pocket cap for Medicare Part D enrollees does not apply to Part B drugs like Leqvio. Patients on Medicare with high cardiovascular drug burdens should model their total Part B exposure with a licensed insurance counselor before choosing between inclisiran and a self-injectable PCSK9 inhibitor.

Is Compounded Inclisiran Legal in Mississippi?

Yes. Compounded inclisiran is legal in Mississippi when prepared by a 503A-licensed compounding pharmacy operating under the supervision of a licensed pharmacist and dispensing pursuant to a valid patient-specific prescription [11]. Mississippi follows federal 503A standards as codified in the Drug Quality and Security Act of 2013, and inclisiran's active pharmaceutical ingredient is commercially available to compounding pharmacies [11].

The FDA has not placed inclisiran on its Demonstrably Difficult to Compound list, nor has it appeared on the agency's Bulks List exclusion register as of January 2025 [12]. That regulatory status means 503A pharmacies may legally compound inclisiran for individual patients. The Mississippi State Board of Pharmacy confirms that 503A compounding of non-excluded active pharmaceutical ingredients is permissible under state law as long as the pharmacy holds a valid Mississippi dispensing license [13].

Compounded inclisiran typically costs significantly less than brand-name Leqvio because the compounding pharmacy sources raw API rather than the finished Novartis product. Several telehealth platforms partnering with licensed Mississippi prescribers offer compounded inclisiran programs at substantially reduced or zero direct cost to patients, depending on the program's structure. Patients should confirm the pharmacy's 503A licensure, request a Certificate of Analysis for the API batch, and verify the prescription is written for a specific patient before accepting any compounded product.

A 2024 FDA guidance update on compounded PCSK9-pathway drugs reminded prescribers that compounded products are not FDA-approved and have not undergone the same manufacturing scrutiny as branded biologics [12]. That distinction is worth discussing with a prescriber before switching from Leqvio to a compounded version.

How Does the Novartis Leqvio Savings Program Work in Mississippi?

The Novartis LEQVIO Savings Program is available to commercially insured patients in Mississippi who meet eligibility criteria. Eligible patients pay as little as $0 per injection, with Novartis covering the remainder of the commercial plan's cost-sharing [14]. The savings card is not available to patients whose primary coverage is a federal or state government program, including Medicare, Medicaid, TRICARE, or any other government-funded plan [14].

Enrollment takes place through the Novartis patient support hub at 1-833-LEQVIO1. Mississippi-based prescribers can enroll patients at the point of care or patients can self-enroll online. The program covers both the loading doses and maintenance doses as long as the patient retains commercial insurance and meets income criteria [14].

One practical note: because Leqvio is administered in a clinical setting under Part B for Medicare patients, the savings card does not stack with Medicare cost-sharing. Mississippi Medicare beneficiaries should instead ask their cardiologist or primary care physician about the Novartis patient assistance program (PAP), which provides Leqvio at no cost to qualifying patients below certain income thresholds [14].

The PAP income threshold as of 2025 is 600% of the federal poverty level (FPL), meaning a single Mississippi resident earning up to approximately $90,480 annually may qualify [14]. Applications require proof of income and an insurance denial letter or documentation of no coverage.

Can I Get a Leqvio Prescription via Telehealth in Mississippi?

Yes. Mississippi permits telehealth prescribing of Leqvio by licensed physicians, nurse practitioners, and physician assistants who hold a valid Mississippi DEA registration and have established a valid patient-provider relationship through a synchronous audio-visual encounter [15]. The Mississippi State Board of Medical Licensure amended its telehealth practice standards in 2023 to align with post-pandemic permanency rules, which maintained the audio-visual requirement for controlled substances but left non-controlled specialty drugs like inclisiran accessible via standard telehealth visits [15].

The administration requirement creates a practical nuance. A telehealth provider in Mississippi can write the Leqvio prescription, but the patient still needs a local clinic, cardiologist office, or infusion center to administer the subcutaneous injection. HealthRX coordinates with local administration sites in Mississippi to complete this last step after the telehealth consult. Most patients in the Jackson metro area, the Gulf Coast, and the Memphis corridor (DeSoto County) can access an administration site within 20 to 30 miles [15].

Rural Mississippi patients face a genuine gap. A 2023 JAMA Network Open study found that 24.7% of Mississippi residents live more than 30 miles from a cardiology-capable clinic [16]. For those patients, compounded inclisiran administered by a home-health nurse or visiting clinical staff may be a more practical option under the 503A pathway described above.

Comparing Inclisiran to Other LDL-C Lowering Options in Mississippi

Mississippi prescribers typically cycle through three tiers of LDL-C therapy before reaching inclisiran: maximally tolerated statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg), ezetimibe 10 mg added to statin therapy, and then PCSK9 inhibition or inclisiran [5].

Evolocumab (Repatha) 140 mg every two weeks or 420 mg monthly is self-injectable and covered by Mississippi Medicaid with prior authorization. A 2021 Cochrane review of PCSK9 inhibitors across 40 trials (N=67,237) found a 15% relative risk reduction in major adverse cardiovascular events for evolocumab vs. placebo (RR 0.85 to 95% CI 0.80-0.90) [17]. Inclisiran has not yet completed a cardiovascular outcomes trial, though ORION-4 (NCT03705234, N=15,000, ongoing) is expected to report primary outcomes in 2026 [18].

For a Mississippi patient on Medicare Part B who cannot self-inject, the comparison shifts: both evolocumab and inclisiran require clinical administration under Part B, but inclisiran's twice-yearly dosing means fewer clinic visits. The ACC/AHA guideline notes no head-to-head RCT comparing inclisiran directly to evolocumab or alirocumab [5].

Bempedoic acid (Nexletol) 180 mg daily is an oral non-statin option covered by most Mississippi commercial plans and by Medicaid with prior authorization. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major cardiovascular events by 13% vs. placebo (HR 0.87 to 95% CI 0.79-0.96, P=0.004) in statin-intolerant patients [19]. For patients who want an oral agent and cannot access injectable therapy, bempedoic acid is a reasonable bridge while pursuing inclisiran coverage.

How Mississippi Prescribers Should Document Inclisiran Prior Authorizations

Prior-authorization approval rates for inclisiran in Mississippi commercial plans are higher when the submission includes four specific elements: a documented LDL-C result above the plan's threshold (typically above 70 mg/dL for ASCVD patients or above 100 mg/dL for primary prevention), evidence of maximally tolerated statin therapy for at least 90 days, a documented ezetimibe trial, and citation of the ACC/AHA 2022 guideline recommendation [5][4].

The ACC/AHA 2022 guideline states specifically: "For patients with very high-risk ASCVD who require additional LDL-C lowering despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [5]. Mississippi prescribers who substitute "inclisiran" for "PCSK9 inhibitor" in the narrative and attach the ORION-10/ORION-11 trial abstract typically see faster approvals than those who rely on narrative alone.

A 2023 retrospective audit published in the American Journal of Managed Care found that prior-authorization approval rates for PCSK9-class drugs rose from 52% to 81% when prescribers submitted structured clinical summaries rather than free-text notes, across a multi-state commercial payer dataset [20]. Mississippi payers were not separately segmented, but the pattern applies broadly.

What Is the Cheapest Way to Get Inclisiran in Mississippi in 2026?

For commercially insured Mississippi patients, the cheapest path is Leqvio through the Novartis savings card, which may reduce cost to $0 per injection [14]. For uninsured patients or those on Mississippi Medicaid, the cheapest legal path is compounded inclisiran from a licensed 503A pharmacy combined with a telehealth prescription, or enrollment in the Novartis patient assistance program if income qualifies [11][14].

Medicare Part B patients should compare their 20% cost-sharing on inclisiran (approximately $621 per dose in 2024) against Medigap or Medicare Advantage plan benefits before choosing between inclisiran and a self-injectable PCSK9 inhibitor covered under Part D [10]. For very high-risk patients who have already exceeded their annual Part B out-of-pocket, the math may favor inclisiran after that threshold is met.

Mississippi residents with questions about cost-of-care navigation can contact the Mississippi Health Insurance Exchange (HealthCare.gov) during open enrollment or call the State Health Insurance Assistance Program (SHIP) at 1-800-948-3090 for free counseling [21].

The single most actionable step for a Mississippi patient starting the Leqvio access process: contact the Novartis hub at 1-833-LEQVIO1 before filling any prescription, confirm eligibility for the savings program or PAP, and ask the prescriber to submit a prior-authorization using the ACC/AHA 2022 Class I Level A language alongside ORION-10 trial data showing 52.3% LDL-C reduction at day 510.